|
|
 |
|
Viewing report
|
|
|
|
Poland Pharmaceuticals and Healthcare Report Q3 2010
Business Monitor International, May 2010, Pages: 85
The Poland Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Poland's pharmaceuticals and healthcare industry.
BMI’s Pharmaceuticals & Healthcare Business Environment Ratings for Q310 put Poland as the second most attractive market in emerging Europe and 20th globally. Despite ongoing regulatory issues in the country and relatively poor demographic factors, the pharmaceutical market dynamics and strong country risk scores result in strong optimism for the industry in Poland.
Following strong market resilience in 2009, pharmaceutical sales showed sharp contractions in early 2010, followed by a steady return to market growth. BMI forecasts sales to grow by 6.4% in 2010, to a value of PLN32.2bn (US$11.6bn). By absolute value this equates to an increase of US$1.3bn, making Poland the 10th fastest growing market globally and second only to Russia in emerging Europe. Over a five-year period, BMI projects that pharmaceutical sales in Poland will increase at a compound annual growth rate (CAGR) of 6.7% in zloty terms or 9.2% in US dollar terms. By absolute value, the market will have grown by US$5.7bn by 2014 to US$16.0bn
Pricing and market access remain key areas of contention in Poland. Poland’s intellectual property (IP) and market access regimes remain substandard, highlighted by its presence on Pharmaceutical Research and Manufacturers of America (PhRMA)’s Priority Watch List for 2010 because of numerous grievances. These include: failure to remover illegal ‘ghost’ drugs after EU accession; failure to implement the EU’s 8+2+1 data protection terms; a backlog for reimbursement approval of innovative drugs; the role of the Health Technology Assessment Agency (AOTM); limited access to healthcare professionals for marketing purposes; and a lack of dialogue with the Ministry of Health.
The short-term outlook for improvement appears relatively bleak. In Q109, the Ministry of Health said it is considering introducing a 3% tax on returns from reimbursed medicines. The levy would be charged to pharmaceutical companies and the ministry would seek to raise PLN180mn (US$63mn) per year. Revenues from the 3% tax would go to the AOTM, the body with the power to approve or reject a drug for reimbursement based upon a number of factors, including cost effectiveness.
Over the long term, market access issues may ease, if extra investment for the AOTM results in an increased number of innovative products gaining market access. This should boost multinational drugmakers over the long term. Meanwhile, the process of privatising state drugmakers held by Polish Pharmaceutical Holding (PHF) is ongoing, with one of the three drugmakers, Polfa Pabianice, having been acquired.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Poland Pharmaceuticals and Healthcare Report Q4 2010
Poland Pharmaceuticals and Healthcare Report Q3 2011
Poland Pharmaceuticals and Healthcare Report Q2 2010
Kazakhstan Pharmaceuticals and Healthcare Report Q1 2012
Kazakhstan Pharmaceuticals and Healthcare Report Q1 2011
Slovenia Pharmaceuticals and Healthcare Report Q1 2012
Russia Pharmaceuticals and Healthcare Report Q4 2010
Italy Pharmaceuticals and Healthcare Report Q1 2011
Pakistan Pharmaceuticals and Healthcare Report Q2 2012
Poland Pharmaceuticals and Healthcare Report Q2 2009
|
|
|
|
